Calcium-Containing Cationic Lipid Nanoparticles for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene delivery methods, including viral and non-viral vectors, face challenges such as low transfection efficiency, immunogenicity, toxicity, and stability issues, limiting the application of gene therapy drugs, particularly for long-chain nucleic acids.
Innovation Solution
Development of calcium-containing cationic lipid nanoparticles with a non-precipitated calcium core for encapsulating nucleic acids, which enhances transfection efficiency and targets specific organs like the liver.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lipid nanoparticles are used for gene delivery, then the nucleic acid can be encapsulated, but the transfection efficiency remains very low (less than 5% escape from endosome)
Solution Approach 1:
The patent modifies the chemical composition parameters of the lipid nanoparticle by incorporating calcium ions and specific lipid ratios (ionizable cationic lipid 30-70%, neutral phospholipid 10-40%, cholesterol 10-30%, PEGylated lipid 5-20%). These parameter changes enable the nanoparticle to achieve both high encapsulation efficiency and significantly improved transfection efficiency compared to conventional LNPs.
Solution Approach 2:
The patent creates a composite lipid nanoparticle system combining multiple lipid types (ionizable cationic lipid, neutral phospholipid, cholesterol, PEGylated lipid) with calcium ions. This composite structure leverages the complementary functions of each component: ionizable cationic lipid for endosomal escape, neutral phospholipid for membrane fusion, cholesterol for stability, and PEGylated lipid for circulation time extension.
2Productivity
If viral vectors are used for gene delivery, then high transfection efficiency can be achieved, but immunogenicity and safety risks (random insertion causing cancer) increase
Solution Approach 1:
The patent employs non-viral lipid nanoparticle carriers that are biodegradable and transient, replacing persistent viral vectors. These synthetic lipid nanoparticles provide sufficient gene delivery functionality without the long-term safety risks, immunogenicity, and manufacturing complexity associated with viral vectors, offering a safer alternative for clinical application.
Solution Approach 2:
The lipid nanoparticle acts as an intermediary carrier that facilitates gene delivery without directly integrating into the host genome. Unlike viral vectors that may insert randomly into DNA, the lipid nanoparticle delivers nucleic acids temporarily and degrades, eliminating the risk of insertional mutagenesis while maintaining delivery effectiveness.
3Adaptability or versatility
If chemical modification of nucleic acids (GalNac-ESC modification) is used, then liver-targeted delivery can be achieved, but stable delivery of long-chain mRNAs and DNAs becomes difficult
Solution Approach 1:
The patent develops a universal lipid nanoparticle platform that can deliver various types of nucleic acids (siRNA, mRNA, long-chain DNA) to the liver through a single mechanism. The nanoparticle structure provides size-dependent liver targeting and protects all nucleic acid types from degradation, overcoming the limitations of chemical modification methods that work only for specific nucleic acid lengths and types.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The calcium-containing cationic lipid nanoparticles achieve high transfection efficiency and stable delivery of nucleic acids, overcoming the limitations of existing methods by providing controlled particle size and targeted delivery.
Implementation Method 1
the ionizable cationic lipid is used for interaction with a negatively charged gene under acidic conditions to achieve a high gene encapsulation effect
Implementation Method 2
In addition, it interacts with the membrane of an endosome to mediate endosomal escape during endosomal acidification
Data Source
AI summary
A nucleic acid-loaded calcium-containing cationic lipid nanoparticle, comprising a cationic lipid, a neutral lipid, a PEGylated lipid, and cholesterol and/or a cholesterol ester. The cationic lipid nanoparticle can be used for preparing a gene-based drug for local injection into the body or a nucleic acid vaccine for local or systemic injection into the body.